サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1654675

前立腺ヘルスの世界市場：2025年～2033年

Global Prostate Health Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
前立腺ヘルスの世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

前立腺ヘルスの世界市場は、2024年に413億4,000万米ドルに達し、2033年までには994億1,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは9.1%で成長する見込みです。

前立腺ヘルスは、特に年齢を重ねるにつれて、男性の全体的な幸福にとって不可欠な側面です。前立腺に関連する最も一般的な問題には、前立腺炎、前立腺肥大症（BPH）、前立腺がんなどがあります。これらの疾患は、排尿痛、頻尿、骨盤の不快感などの重大な症状を引き起こす可能性があります。

前立腺ヘルス市場は、これらの疾患の有病率の増加と高齢化人口の増加により急速に拡大しています。治療の選択肢は特定の疾患によって異なり、前立腺肥大症にはα遮断薬や5α還元酵素阻害薬などの薬物療法、前立腺炎には抗生物質、前立腺がんには手術、放射線療法、ホルモン治療など様々な治療法があります。前立腺ヘルスの問題に対する意識が高まるにつれ、効果的な診断ツールや治療的介入に対する需要も増加しています。

市場力学：

促進要因と抑制要因

前立腺疾患の有病率の増加

前立腺疾患、特に前立腺肥大症（BPH）、前立腺がん、前立腺炎の有病率の上昇は、前立腺ヘルス市場の成長を支える重要な原動力です。前立腺疾患は、特に男性人口の高齢化に伴い、より一般的になっており、効果的な診断・治療ソリューションに対する需要が高まっています。

前立腺がんは、世界的に男性の間で最も罹患率の高いがんであり、毎年数百万人の新規症例に寄与しています。例えば、米国がん協会の推計によると、2025年には約31万3,780件の前立腺がんの新規症例が報告されると予想されています。

さらに、2024年の欧州泌尿器科学会によると、全男性の約2％から6％が罹患するとされています。このような有病率の急増は、前立腺ヘルスに対する意識や関心を高めるだけでなく、新しい治療法や技術の研究開発への投資を促進します。したがって、上記の要因が予測期間中の市場成長を促進すると予想されます。

治療による副作用

前立腺ヘルス、特に前立腺がんなどの治療による副作用は、前立腺ヘルス市場の大きな抑制要因となっています。患者のかなりの割合が、様々な治療法の後に長期的な合併症を経験します。前立腺摘除術を受けた男性は、未治療の人に比べて排尿や性的合併症が7倍も増加します。さらに、放射線療法は腸機能障害につながる可能性があり、膀胱がんなどの二次がんのリスクが未治療の男性に比べて3倍近く増加します。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 前立腺肥大症の罹患率の増加
    • 抑制要因
      • 治療の副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 適応症別

  • 前立腺がん
  • 良性前立腺肥大症（BPH）
  • 前立腺炎

第7章 治療別

  • 放射線治療
  • 化学療法
  • 免疫療法
  • ホルモン療法
  • 標的薬物療法
  • その他

第8章 エンドユーザー別

  • 病院
  • 腫瘍学センター
  • 外来手術センター
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第11章 企業プロファイル

  • Novartis AG
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 過去および予測の製品販売
      • 製品販売量
    • 財務概要
      • 会社の収益
      • 地域別収益分配
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • GSK plc.
  • Astellas Pharma Inc.
  • Merck & Co., Inc.
  • JOHNSON & JOHNSON SERVICES, INC.
  • Pfizer Inc.
  • Sanofi SA
  • Bayer
  • Zydus Lifesciences Limited
  • Wellona Pharma
  • Candel Therapeutics, Inc.
    • パイプライン製品の説明
    • 製品の主要業績評価指標（KPI）
    • 主な活動
    • 市場参入のタイムライン
    • 製品普及率
    • 売上予測と予測
  • Essa Pharma
  • 各市場参入企業に対しても同様のデータが提供されます。

第12章 付録

目次
Product Code: PH7774

The global prostate health market reached US$ 41.34 billion in 2024 and is expected to reach US$ 99.41 billion by 2033, growing at a CAGR of 9.1% during the forecast period 2025-2033.

Prostate health is a vital aspect of men's overall well-being, particularly as they age. The most common prostate-related issues include prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. These conditions can lead to significant symptoms such as painful urination, frequent urges to urinate, and pelvic discomfort.

The prostate health market is expanding rapidly due to the increasing prevalence of these conditions and a growing aging population. Treatment options vary depending on the specific condition and may include medications like alpha-blockers and 5-alpha-reductase inhibitors for BPH, antibiotics for prostatitis, and various therapies for prostate cancer, including surgery, radiation therapy, and hormone treatments. As awareness of prostate health issues increases, the demand for effective diagnostic tools and therapeutic interventions increases.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Prostate Disorders

The rising prevalence of prostate disorders, particularly benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis, is a significant driving force behind the growth of the prostate health market. As prostate disorders become more common, especially among the aging male population, there is an increasing demand for effective diagnostic and therapeutic solutions.

Prostate cancer, being the most prevalent cancer among men globally, contributes to millions of new cases each year. For instance, according to the estimates by the American Cancer Society, it is stated that about 313,780 new cases of prostate cancer are expected to be reported in 2025.

Additionally, according to the European Association of Urology in 2024, it is stated that about 2-6% of all men are affected. This surge in prevalence not only heightens awareness and concern about prostate health but also propels investments in research and development for new treatments and technologies. Thus, the above factors are expected to drive market growth during the forecast period.

Adverse Effects of Treatments

Adverse effects of treatments for prostate health, particularly for conditions like prostate cancer, are significant restraints on the prostate health market. A substantial percentage of patients experience long-term complications following various treatment modalities. The risks associated with these treatments can be daunting; men who undergo prostatectomy face a sevenfold increase in urinary or sexual complications compared to untreated individuals. Additionally, radiotherapy can lead to bowel dysfunction and increases the risk of secondary cancers, such as bladder cancer, by nearly three times compared to untreated men

Segment Analysis

The global prostate health market is segmented based on indication, treatment, end users, and region.

Treatment:

Hormone Therapy segment is expected to dominate the global prostate health market share

The prostate health market is expected to see significant growth, driven primarily by the increasing prevalence of prostate cancer and the rising demand for effective treatment options. Among the various treatment modalities available, hormone therapy is projected to hold a dominant position in the prostate health market.

Currently, hormone therapy is recognized as the leading treatment for prostate cancer due to its effectiveness in managing advanced stages of the disease, particularly in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHNPC). Companies are receiving approvals for their innovations and are meeting the regulatory needs and demands. For instance, in October 2023, Sumitomo Pharma Canada, Inc. its ORGOVYX (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist received approval from Health Canada. The approval is based on efficacy and safety data from the Phase 3 HERO study of ORGOVYX in men with advanced prostate cancer.

Additional factors contributing to its dominance include a growing geriatric population, advancements in drug formulations, and an increase in public awareness regarding prostate health.

Geographical Analysis

North America is expected to hold a significant position in the global prostate health market share

North America dominates the prostate health market due to several key factors contributing to its substantial market share. The region has a high incidence of prostate-related conditions, including benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. This growing target population drives demand for effective diagnostic and therapeutic solutions.

Additionally, North America benefits from a robust healthcare infrastructure, which includes advanced medical facilities and a strong presence of leading medical device manufacturers, fostering innovation and product development. For instance, in June 2023 AstraZeneca and Merck received U.S. FDA approval for its LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

In August 2023, the Janssen Pharmaceutical Companies received the U.S. Food & Drug Administration (FDA) approval for its AKEEGA (niraparib and abiraterone acetate) for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test. It is the first and only dual-action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone. Collectively, these factors position North America in a dominant position in the prostate health market.

Competitive Landscape

The major global players in the prostate health market include Novartis AG, GSK plc., Astellas Pharma Inc., Merck & Co., Inc., JOHNSON & JOHNSON SERVICES, INC., Pfizer Inc., Sanofi SA, Bayer, Zydus Lifesciences Limited and Wellona Pharma among others.

Key Developments

  • In December 2024, Candel Therapeutics, Inc. announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients.
  • In 2024, Bayer announced that the U.S. Food and Drug Administration (FDA) had accepted the company's supplemental new drug application (sNDA) for the oral androgen receptor inhibitor (ARi) NUBEQA (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
  • In April 2023, The Janssen Pharmaceutical Companies announced the availability of an additional tablet strength of ERLEADA (apalutamide) in the United States.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Prostate Health Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Indication
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End Users
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of benign prostatic hyperplasia
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse Effects of Treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Indication

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 6.1.2. Market Attractiveness Index, By Indication
  • 6.2. Prostate Cancer*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Benign Prostatic Hyperplasia (BPH)
  • 6.4. Prostatitis

7. By Treatment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.1.2. Market Attractiveness Index, By Treatment
  • 7.2. Radiation Therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Chemotherapy
  • 7.4. Immunotherapy
  • 7.5. Hormone Therapy
  • 7.6. Targeted Drug Therapy
  • 7.7. Others

8. By End Users

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 8.1.2. Market Attractiveness Index, By End Users
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Oncology Centers
  • 8.4. Ambulatory Surgical Centers
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

  • 11.1. Novartis AG*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals etc.
    • 11.1.5. SWOT Analysis
  • 11.2. GSK plc.
  • 11.3. Astellas Pharma Inc.
  • 11.4. Merck & Co., Inc.
  • 11.5. JOHNSON & JOHNSON SERVICES, INC.
  • 11.6. Pfizer Inc.
  • 11.7. Sanofi SA
  • 11.8. Bayer
  • 11.9. Zydus Lifesciences Limited
  • 11.10. Wellona Pharma
  • Similar data will be provided for each market player.

Emerging Market Players

  • 11.11. Candel Therapeutics, Inc.*
    • 11.11.1. Pipeline Products Description
    • 11.11.2. Product Key Performance Indicators (KPIs)
    • 11.11.3. Key Activities
    • 11.11.4. Market Entry Timelines
    • 11.11.5. Product Penetration Rate
    • 11.11.6. Sales Estimation and Projections
  • 11.12. Essa Pharma
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us